LYEL
VENTE TOTALE: 9 979 titres (~154 605,66 $ US)
- Insiders
- Seely Lynn
- Total bought
- —
- Total sold
- $154,606
- Last activity
- 2026-08-21
- Last synced
-
2026-08-27 10:00:12
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-27
LYEL presents a critically weak financial profile with extreme cash burn, negative margins, and no clear path to commercial viability, making the liquidity score of 45 misleading given the underlying deterioration.
The first sentence of the analysis written for LYEL on 2026-08-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -31952.8% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -762355.6% | -361104.9% | -180486.2% | -216.2% | -2349.5% | |
| Ebitda Margin | -730302.8% | -328923.0% | -164909.2% | -195.0% | -2221.5% | |
| Operating Profit Margin | -566038.9% | -588123.0% | -190006.2% | -220.9% | -2016.7% | |
| Pretax Profit Margin | -762355.6% | -562285.2% | -180486.2% | -216.2% | -2349.5% | |
| Continuous Operations Profit Margin | -762355.6% | -562285.2% | -180486.2% | -216.2% | -2349.5% | |
| Net Profit Margin | -762355.6% | -562285.2% | -180486.2% | -216.2% | -2349.5% | |
| Bottom Line Profit Margin | -762355.6% | -562285.2% | -180486.2% | -216.2% | -2349.5% | |
| Current Ratio | 5.281 | 7.057 | 16.069 | 17.589 | 13.400 | |
| Quick Ratio | 5.281 | 7.057 | 16.069 | 17.589 | 13.400 | |
| Solvency Ratio | -2.862 | -2.993 | -2.255 | -1.583 | -1.197 | |
| Cash Ratio | 1.218 | 1.963 | 4.219 | 3.337 | 6.287 | |
| Price To Earnings Ratio | -1.917 | -9.771 | -41.506 | -93.645 | -150.175 | |
| Price To Earnings Growth Ratio | -0.002 | -0.243 | -1.588 | 3.332 | -6.776 | |
| Forward Price To Earnings Growth Ratio | -0.002 | -0.243 | -1.588 | 3.332 | -6.776 | |
| Price To Earnings Diluted Ratio | -1.917 | -9.771 | -41.506 | -93.645 | -150.175 | |
| Price To Earnings Diluted Growth Ratio | -0.002 | -0.243 | -1.588 | 3.332 | -6.776 | |
| Price To Book Ratio | 2.120 | 0.437 | 0.743 | 1.029 | 2.021 | |
| Price To Sales Ratio | 14,614.515 | 2,743.397 | 3,745.439 | 10.124 | 176.412 | |
| Price To Free Cash Flow Ratio | -3.489 | -1.028 | -2.926 | -4.423 | -9.798 | |
| Price To Operating Cash Flow Ratio | -3.507 | -1.031 | -2.974 | -5.057 | -14.882 | |
| Debt To Assets Ratio | 0.150 | 0.120 | 0.084 | 0.072 | 0.060 | |
| Debt To Equity Ratio | 0.205 | 0.154 | 0.096 | 0.081 | 0.073 | |
| Debt To Capital Ratio | 0.170 | 0.133 | 0.088 | 0.075 | 0.068 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.370 | 1.282 | 1.145 | 1.125 | 1.213 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.142 | 0.019 | |
| Operating Cash Flow Ratio | -3.036 | -3.019 | -4.742 | -4.579 | -2.701 | |
| Operating Cash Flow Sales Ratio | -4,167.333 | -2,662.197 | -1,259.185 | -2.002 | -11.854 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.005 | 1.003 | 1.016 | 1.143 | 1.519 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -2.942 | -2.754 | -2.591 | -2.504 | -1.862 | |
| Capital Expenditure Coverage Ratio | -192.338 | -349.987 | -60.943 | -6.984 | -1.927 | |
| Dividend Paid And Capex Coverage Ratio | -192.338 | -349.987 | -60.943 | -6.984 | -1.927 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -1.966 | -0.602 | -1.886 | -4.855 | -6.986 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -31952.8% | ▼-32052.8% | ▼-25642.2% |
| Ebit Margin | -762355.6% | ▼-401250.6% | ▼-501053.1% |
| Ebitda Margin | -730302.8% | ▼-401379.8% | ▼-484992.5% |
| Operating Profit Margin | -566038.9% | ▲22084.1% | ▼-296757.8% |
| Pretax Profit Margin | -762355.6% | ▼-200070.3% | ▼-460817.0% |
| Continuous Operations Profit Margin | -762355.6% | ▼-200070.3% | ▼-460817.0% |
| Net Profit Margin | -762355.6% | ▼-200070.3% | ▼-460817.0% |
| Bottom Line Profit Margin | -762355.6% | ▼-200070.3% | ▼-460817.0% |
| Current Ratio | 5.281 | ▼-1.776 | ▼-6.598 |
| Quick Ratio | 5.281 | ▼-1.776 | ▼-6.598 |
| Solvency Ratio | -2.862 | ▲0.131 | ▼-0.684 |
| Cash Ratio | 1.218 | ▼-0.745 | ▼-2.187 |
| Price To Earnings Ratio | -1.917 | ▲7.854 | ▲57.486 |
| Price To Earnings Growth Ratio | -0.002 | ▲0.242 | ▲1.054 |
| Forward Price To Earnings Growth Ratio | -0.002 | ▲0.242 | ▲1.054 |
| Price To Earnings Diluted Ratio | -1.917 | ▲7.854 | ▲57.486 |
| Price To Earnings Diluted Growth Ratio | -0.002 | ▲0.242 | ▲1.054 |
| Price To Book Ratio | 2.120 | ▲1.683 | ▲0.850 |
| Price To Sales Ratio | 14614.515 | ▲11871.118 | ▲10356.538 |
| Price To Free Cash Flow Ratio | -3.489 | ▼-2.461 | ▲0.844 |
| Price To Operating Cash Flow Ratio | -3.507 | ▼-2.476 | ▲1.983 |
| Debt To Assets Ratio | 0.150 | ▲0.030 | ▲0.053 |
| Debt To Equity Ratio | 0.205 | ▲0.051 | ▲0.083 |
| Debt To Capital Ratio | 0.170 | ▲0.037 | ▲0.063 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.370 | ▲0.088 | ▲0.143 |
| Working Capital Turnover Ratio | 0.000 | -0.000 | ▼-0.032 |
| Operating Cash Flow Ratio | -3.036 | ▼-0.017 | ▲0.579 |
| Operating Cash Flow Sales Ratio | -4167.333 | ▼-1505.137 | ▼-2546.819 |
| Free Cash Flow Operating Cash Flow Ratio | 1.005 | ▲0.002 | ▼-0.132 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -2.942 | ▼-0.188 | ▼-0.411 |
| Capital Expenditure Coverage Ratio | -192.339 | ▲157.649 | ▼-69.902 |
| Dividend Paid And Capex Coverage Ratio | -192.339 | ▲157.649 | ▼-69.902 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -1.966 | ▼-1.365 | ▲1.293 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $526.1M | $167.3M | $486.9M | $857.4M | $1.88B | |
| Enterprise value | $516.9M | $120.7M | $404.4M | $801.5M | $1.65B | |
| EV / Sales | 14359.32x | 1978.99x | 3110.98x | 9.46x | 155.19x | |
| EV / Op. cash flow | -3.45x | -0.74x | -2.47x | -4.73x | -13.09x | |
| EV / Free cash flow | -3.43x | -0.74x | -2.43x | -4.13x | -8.62x | |
| EV / EBITDA | -1.97x | -0.60x | -1.89x | -4.86x | -6.99x | |
| Net debt / EBITDA | 0.04x | 0.23x | 0.39x | 0.34x | 0.95x | |
| Current ratio | 5.28x | 7.06x | 16.07x | 17.59x | 13.40x | |
| Income quality | 0.55x | 0.47x | 0.70x | 0.93x | 0.51x | |
| Graham net-net | $9 | $20 | $36 | $43 | $34 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 155.7% | 100.0% | 100.0% | 100.0% | |
| Working capital | $211.5M | $325.8M | $520.2M | $614.3M | $579.5M | |
| Invested capital | $265.2M | $398.7M | $662.5M | $780.5M | $746.2M | |
| Return on assets | -80.7% | -69.9% | -31.3% | -19.5% | -22.2% | |
| Operating ROA | -49.0% | -57.8% | -29.3% | -18.1% | -21.1% | |
| Return on tangible assets | -80.7% | -69.9% | -31.3% | -19.5% | -22.2% | |
| Return on equity | -110.6% | -89.6% | -35.8% | -22.0% | -26.9% | |
| Return on invested capital | -68.0% | -80.6% | -34.2% | -20.7% | -19.9% | |
| Return on capital employed | -70.1% | -82.1% | -34.5% | -20.8% | -19.9% | |
| Earnings yield | -52.2% | -205.0% | -48.2% | -21.4% | -13.3% | |
| Free cash flow yield | -28.7% | -97.3% | -34.2% | -22.6% | -10.2% | |
| Capex / Op. cash flow | -0.5% | -0.3% | -1.6% | -14.3% | -51.9% | |
| Capex / Depreciation | 6.8% | 2.4% | 13.3% | 147.4% | 480.8% | |
| Capex / Sales | 2166.7% | 760.7% | 2066.2% | 28.7% | 615.1% | |
| SG&A / Sales | 125375.0% | 85313.1% | 51525.4% | 138.5% | 836.2% | |
| R&D / Sales | 440763.9% | 281316.4% | 140726.9% | 188.0% | 1302.3% | |
| Stock comp / Sales | 116191.7% | 54334.4% | 36218.5% | 0.0% | 584.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 92d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -92d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+214.4%EV / Sales ▲+625.6%EV / EBITDA ▼-226.8%EV / Op. cash flow ▼-2.702Earnings yield ▲+1.528
Profitability
Return on equity ▼-0.210Return on assets ▼-0.108Return on invested capital ▲+0.126Return on capital employed ▲+0.120Operating ROA ▲+0.088Income quality ▲+0.073Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales ▲+14.060R&D / Sales ▲+1594.475
Balance-sheet strength
Current ratio ▼-1.776Net debt / EBITDA ▼-0.197Working capital ▼-114279000.000Invested capital ▼-133576000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-72.0%EV / Sales ▲+9152.7%EV / EBITDA ▲+71.9%EV / Op. cash flow ▲+9.646Earnings yield ▼-0.388
Profitability
Return on equity ▼-0.837Return on assets ▼-0.585Return on invested capital ▼-0.481Return on capital employed ▼-0.502Operating ROA ▼-0.279Income quality ▲+0.042Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales ▲+15.516R&D / Sales ▲+4394.616
Balance-sheet strength
Current ratio ▼-8.119Net debt / EBITDA ▼-0.920Working capital ▼-368021000.000Invested capital ▼-481018000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-06 This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- 2026-08-06 Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment before the opening bell.
- 2026-07-22 Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives $43.00 Consensus Price Target from Analysts Lyell Immunopharma, Inc. (NASDAQ: LYEL - Get Free Report) has received an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have assigned a buy recommendation and one has issued
- 2026-07-02 Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 176% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 2026-06-25 Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in a fireside chat at the H.C.
- 2026-06-13 Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection Lyell Immunopharma (LYLE) offers asymmetric upside, with ronde-cel showing best-in-class durability and safety in relapsed/refractory LBCL. LYLE trades near cash value, with the market heavily discounting its pipeline despite advanced pivotal trials and strong early efficacy signals. Ronde-cel''s dual CD19/CD20 targeting and CD62L+ enrichment underpin durable responses, low severe toxicity, and potential for outpatient administration.
- 2026-06-12 Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress More than 100 patients treated with ronde-cel in 2L and 3L+ LBCL, with a manufacturing success rate of 97% No Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS, supporting outpatient administration Translational data support biological basis for durable responses, including enhanced memory potential of cytotoxic effector cells from CD62L+ enrichment, and CD19/CD20 dual-targeting to overcome low antigen expression PiNACLE pivotal clinical trial in 3L+ setting data update expected in second half of 2026; pivotal data readout expected in mid-2027, with BLA submission to follow in the second half of 2027 SOUTH SAN FRANCISCO, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, is announcing today new safety data from the ongoing Phase 1/2 clinical trial of rondecabtagene autoleucel (ronde-cel) in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third- and later-line (3L+) settings and new translational data for ronde-cel.
- 2026-06-10 Lyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Lyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- 2026-06-08 Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update on Lyell Immunopharma Inc. (NASDAQ: LYEL) stock is up on Monday as the company is providing an update on the safety profile of its LYL273 treatment in a Phase 1 clinical trial for relapsed or refractory metastatic colorectal cancer (mCRC).
- 2026-06-08 Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today provided an update on the safety profile of LYL273 in its ongoing U.S. Phase 1 clinical trial in patients with relapsed or refractory metastatic colorectal cancer (mCRC), and announced the Phase 1 trial has been amended to enable seamless expansion into a potential pivotal single-arm Phase 2 trial pending regulatory alignment.